Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2280]

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced...

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of...

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate...

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

PFS increase but no OS increase for niraparib in advanced ovarian cancer

Dr Antonio González-Martín - Cancer Center Clínica Universidad de Navarra...

PFS increase but no OS increase for niraparib in advanced ovarian cancer ( Dr Antonio González-Martín - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal...

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )

Immunotherapy resistance pathways investigated to tailor combination NSCLC...

Prof Pascale Tomasini - Aix-Marseille University, Marseille, France

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy ( Prof Pascale Tomasini - Aix-Marseille University, Marseille, France )

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van...

ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )

No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBC

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA

No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBC ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )

More from ecancer